LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
© LexDana · beta
LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets59Federal Circuit877ITC / Section 33788Patent Litigation216Patent Prosecution126Pharma & ANDA62PTAB686Supreme Court61Trademark158USPTO Policy78Unsorted257

Tagged patent term extension · clear

Federal Circuit

Sharing Active Moiety with an Fda Approved Product Is Not Enough to Be Considered an Approved Product for the Purposes of Patent Term Extension Under 35 U S C 156

BIOGEN INTERNATIONAL GMBH v. BANNER LIFE SCIENCES LLC Before Lourie, Moore, and Chen. Appeal from the U.S. District Court for the District of Delaware Summary: If a claimed product is not the active ingredient of an FDA-approved product, or an ester or…

April 21, 2020·Federal Circuit·2 min read
Federal Circuit

NOVARTIS AG v. EZRA VENTURES LLC

Federal Circuit Summary Before Moore, Chen , and Hughes. Appeal from the United States District Court for the District of Delaware. Summary : Obviousness-type double patenting does not invalidate an otherwise validly obtained patent term extension under 35…

December 10, 2018·Federal Circuit·3 min read
LexDana
AskSearchRankingsInsightsPricingProfileContactTermsPrivacy
The LexDana Docket
Monthly — what shipped, who moved, what we published.
© 2026 LexDana, Inc.·Powered by Patexia data